PMCB — PharmaCyte Biotech, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1157075 ·
Last close
$5.42
Market Cap
$58.19M
52W High
$28.69
52W Low
$4.69
ADV30
14,053
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -1,006,708 | -5,081,191 | 36,712,295 | 17,738,991 | 6,896,682 |
| Apr 2026 | 0 | — | -961,828 | -4,393,443 | 46,753,242 | 18,603,899 | 11,772,424 |
| Jan 2026 | 0 | — | -2,118,102 | 746,860 | 55,873,565 | 20,165,535 | 16,471,229 |
| Oct 2025 | 0 | — | -1,376,051 | -7,417,975 | 55,976,469 | 15,406,017 | 19,422,384 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,939,827
Investing CF
$2,000,000
Financing CF
$6,498,178
CapEx
—
Dividends Paid
$-83,399
Buybacks
$-401,625
EPS Diluted TTM
$-3.18
As of
2026-09-20
Balance + Analyst (yfinance extras)
Retained Earnings
$-109,474,805
Inventory
—
Receivables
$429,150
ST Investments
$12,774,462
EBIT TTM
$-5,462,689
Pretax Income TTM
$-16,145,749
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | -5,304,286 | -19,424,654 | 46,800,000 | 11,772,424 | 34,980,818 | -5,152,914 |
| Apr 2025 | 0 | -4,377,862 | 30,656,050 | 55,168,353 | 3,277,284 | 51,891,069 | -2,978,296 |
| Apr 2024 | 0 | -6,520,008 | 333,763 | 59,903,883 | 20,389,264 | 39,514,619 | -2,151,457 |
| Apr 2023 | 0 | -6,455,494 | -4,315,993 | 73,276,925 | 586,581 | 72,690,344 | -3,793,731 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-16,145,749
OpCashFlow TTM
—
Assets (Latest)
$36,712,295
Forward EPS
$-0.38
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OKYO | OKYO Pharma Ltd | $57.99M | $1.11 | — |
| CGTX | COGNITION THERAPEUTICS INC | $59.90M | $0.63 | — |
| NMRA | Neumora Therapeutics, Inc. | $62.85M | $0.33 | — |
| VISK | Viskase Holdings, Inc. | $63.49M | $4.43 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $63.91M | $4.59 | — |
News headlines (Yahoo Finance, 1h cache)
PharmaCyte Biotech Reports Strong Cash and Asset Position
2026-11-13 14:15 · Yahoo
PharmaCyte Biotech, Inc. Announces Reverse Stock Split
2026-11-11 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.